SCHEMBL142916

SCHEMBL142916

O=c1ccccn1-c1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 1/20 0.46
PKM P14618 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HSP90AA1 P07900 1/20 0.43
MAPK1 P28482 1/20 0.43
MGLL Q99685 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MITF O75030 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
DNMT1 P26358 1/20 0.43
HTT P42858 1/20 0.43
MCL1 Q07820 1/20 0.43
SAE1 Q9UBE0 1/20 0.43
UBA2 Q9UBT2 1/20 0.43
FGFR1 P11362 1/20 0.43
F10 P00742 9/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143175 0.81 ALDH1A1 (0.54) MEN1KMT2AMAPTMGLLALDH1A1
SCHEMBL2645575 0.80 DDB1 (0.41) MEN1KMT2AMAPTALDH1A1MCL1
SCHEMBL4212713 0.78 F10 (0.56) MEN1KMT2AALDH1A1HTTF10
SCHEMBL92819 0.78 KDM4E (0.57) MAPTPKMNPSR1MGLLTDP1
SCHEMBL76912 0.78 SMN1; SMN2 (0.52) ALDH1A1HTTF10GAA
SCHEMBL2539751 0.78 F10 (0.39) MEN1KMT2AMAPTALDH1A1MCL1
SCHEMBL142777 0.78 F10 (0.44) LMNAMGLLALDH1A1F10
SCHEMBL1277801 0.78 FAAH (0.43) MEN1KMT2AMAPTMGLLALDH1A1
SCHEMBL29348735 0.78 F10 (0.52) MEN1KMT2AMAPTLMNAPKM
SCHEMBL505240 0.78 CA12 (0.53) NPSR1TDP1POLBDNMT1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP claimed
US-11492358-B1 Macrocyclic indole derivatives THE BROAD INSTITUTE, INC. (US) 2022-11-08 US disclosed
EP-3458459-B1 MACROCYCLIC INDOLE DERIVATIVES BAYER AG (DE) 2022-04-27 EP disclosed
CN-109715632-B Macrocyclic indole derivatives 拜尔公开股份有限公司 2021-10-26 CN disclosed
US-10981932-B2 Macrocyclic indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2021-04-20 US disclosed
US-20200087322-A1 MACROCYCLIC INDOLE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-03-19 US disclosed
CN-109715632-A Macrocyclic indole derivatives 拜尔公开股份有限公司 2019-05-03 CN disclosed
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-20080125429-A1 Aryloxy-Substituted Benzimidazole Derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-05-29 US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1820797-A1 SUBSTITUTED PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-22 EP disclosed
WO-2007062167-A9 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE INC (US) 2007-07-26 WO disclosed
EP-1810969-A1 ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-07-25 EP disclosed
WO-2007062167-A2 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. (US) 2007-05-31 WO disclosed
WO-2007053685-A2 METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS INTERMUNE, INC. (US) 2007-05-10 WO disclosed
CN-1930126-A Pyridone Derivatives BANYU PHARMA CO LTD (JP) 2007-03-14 CN disclosed
CN-1926127-A Novel 2-heteroaryl substituted benzimidazole derivatives BANYU PHARMA CO LTD (JP) 2007-03-07 CN disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010536-B2 Method of modulating stress-activated protein kinase system MAPKAPK2, MAP3K6, MAP4K1 MEN1 4715/4885KMT2A 4406/4885MAPT 2080/4885
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 MEN1 4715/4885KMT2A 4406/4885MAPT 2080/4885
US-20080125429-A1 Aryloxy-Substituted Benzimidazole Derivatives GCK, GCKR, SLC5A1 MEN1 4345/4885KMT2A 2309/4885MAPT 3894/4885
US-11492358-B1 Macrocyclic indole derivatives CCND2, CCNT2, IDO1 MEN1 142/4885KMT2A 930/4885MAPT 2810/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 MEN1 4085/4885KMT2A 1946/4885MAPT 3676/4885
US-10981932-B2 Macrocyclic indole derivatives CCND2, IDO1, CCNT2 MEN1 114/4885KMT2A 772/4885MAPT 2202/4885
US-20200087322-A1 MACROCYCLIC INDOLE DERIVATIVES CCND2, CCNA1, CCNT2 MEN1 140/4885KMT2A 897/4885MAPT 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.